MedTrace Logo

Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

NCT00785525 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60000

Last updated 2025-04-13

No results posted yet for this study

Summary

The purpose of the study is to:

* Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors
* Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis
* Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients
* Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors

Conditions

  • Healthy

Interventions

DRUG

Filgrastim

PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.

Sponsors & Collaborators

Principal Investigators

  • John P Miller, MD, PhD · National Marrow Donor Program

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1997-02-28
Primary Completion
2030-01-31
Completion
2030-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785525 on ClinicalTrials.gov